학술논문
CML-395 Efficacy and Safety Results From ASCEMBL, a Phase III Study of Asciminib vs. Bosutinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After ≥2 Prior Tyrosine Kinase Inhibitors (TKIs): Week 96 Update
Document Type
Article
Author
Réa, D.; Hochhaus, A.; Mauro, M.J.; Minami, Y.; Lomaia, E.; Voloshin, S.; Turkina, A.; Kim, D.-W.; Apperley, J.F.; Cortes, J.E.; Abdo, A.; Fogliatto, L.M.; Kim, D.D.H.; Coutre, P.L.; Saussele, S.; Annunziata, M.; Hughes, T.P.; Chaudhri, N.; Chee, L.; García-Gutiérrez, V.; Sasaki, K.; Kapoor, S.; Allepuz, A.; Quenet, S.; Bédoucha, V.; Boquimpani, C.
Source
In: Clinical Lymphoma, Myeloma and Leukemia , Proceedings of the Society of Hematologic Oncology 2022 Annual Meeting. (Clinical Lymphoma, Myeloma and Leukemia, October 2022, 22:S295-S296)
Subject
Language
English
ISSN
21522669
21522650
21522650